FBLN5 was Regulated by PRDM9, and Promoted Senescence and Osteogenic Differentiation of Human Periodontal Ligament Stem Cells

• Published in: Current stem cell research & therapy Vol. 19; no. 3; p. 417
• Main Authors: Zhao, Mengyao, Rong, Rong, Zhang, Chen, Yang, Haoqing, Han, Xiao, Fan, Zhipeng, Zheng, Ying, Zhang, Jianpeng
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Cell Differentiation; Cells, Cultured; Extracellular Matrix Proteins - metabolism; Extracellular Matrix Proteins - pharmacology; Histone-Lysine N-Methyltransferase - metabolism; Humans; Osteogenesis - genetics; p38 Mitogen-Activated Protein Kinases - metabolism; p38 Mitogen-Activated Protein Kinases - pharmacology; Periodontal Ligament; Stem Cells; senescence; PRDM9; mitogenactivated protein kinase (MAPK); osteogenic differentiation; signaling pathway; Periodontal ligament stem cells (PDLSCs); FBLN5
• ISSN: 2212-3946
• DOI: 10.2174/1574888X18666230822100054

Periodontal ligament stem cells (PDLSCs) are ideal seed cells for periodontal tissue regeneration. Our previous studies have indicated that the histone methyltransferase PRDM9 plays an important role in human periodontal ligament stem cells (hPDLSCs). Whether FBLN5, which is a downstream gene of PRDM9, also has a potential impact on hPDLSCs is still unclear. Senescence was assessed using β-galactosidase and Enzyme-linked immunosorbent assay (ELISA). Osteogenic differentiation potential of hPDLSCs was measured through Alkaline phosphatase (ALP) activity assay and Alizarin red detection, while gene expression levels were evaluated using western blot and RT-qPCR analysis. FBLN5 overexpression promoted the osteogenic differentiation and senescence of hPDLSCs. FBLN5 knockdown inhibited the osteogenic differentiation and senescence of hPDLSCs. Knockdown of PRDM9 decreased the expression of FBLN5 in hPDLSCs and inhibited senescence of hPDLSCs. Additionally, both FBLN5 and PRDM9 promoted the expression of phosphorylated p38 MAPK, Erk1/2 and JNK. The p38 MAPK pathway inhibitor SB203580 and the Erk1/2 pathway inhibitor PD98059 have the same effects on inhibiting the osteogenic differentiation and senescence of hPDLSCs. The JNK pathway inhibitor SP600125 reduced the senescence of hPDLSCs. FBLN5 promoted senescence and osteogenic differentiation of hPDLSCs via activation of the MAPK signaling pathway. FBLN5 was positively targeted by PRDM9, which also activated the MAPK signaling pathway.